Indian pillar: dedicated to killing lung cancer in the cradle

[Keywords] Pulmonary nodular vicious tumor early screening intelligent early diagnosis robot Yale international student abandoned medical studies

[Project Introduction] Creative Group Project: Pulmonary Nodule Circles Cycling Tumor Cell (CTC) Intelligent Early diagnosis robot.通过自主研发的CTC富集设备对血液样本进行高精度肺癌CTCs捕获与富集，获得肺癌CTC形态学图片，利用基于大数据AI图像识别系统进行智能识别，给临床医生提供切除早期原位肺癌及Subsequent individualized precise treatment clearly determines the basis for judgment, which can reduce the risk of medium and advanced cancer and avoid major economic losses caused by treatment.

[Sketch of Entrepreneurs] Indian Pillar, Dr. in the United States, winner of the Hunan Provincial Outstanding Youth Fund in 2021, and the leader of the Ministry of Industry and Information Technology in 2022; Executive Deputy Director of the Research Center, part -time assistant professor at the Department of Pathological Department of Yale University, mainly engaged in the research of tumor immunomardics regulation and the research of tumor epigenetics and immune collaboration mechanisms.

[Entrepreneurship golden sentence] We will always be on the road to fight cancer, and cure tumors are the goal of eternal pursuit.

From clinical to scientific research, I want to build a front line

Yinzhu was a gynecologist. After graduating from Harbin Medical University's oncology, he became a doctor at Harbin Medical University Cancer Hospital. That is, in this process, he has a new understanding of the treatment of the life cycle of cancer patients, especially the life treatment of cancer patients in the middle and advanced periods.

"Many patients who have performed surgery, chemotherapy or radiotherapy have not improved in the end, but to the end of life." No matter how good the surgeon can do, the number of patients who can treat it for a lifetime is limited, especially in the face of cancer. If you can develop new technologies or new drugs for early screening or treat tumors, it will benefit thousands of thousands Thousands of patients and their families. "Yin Chuan said.

Therefore, his center of thinking was diagnosed from surgery to the frontier diagnosis, and he also made a decision -switching, continuing for further studies, he has entered the Institute of Anti -Aging of the National Institute of Health, China Pharmaceutical University, and Yale University in the United States. , Pathology, Chinese and Western Medicine Integrated in multiple fields. In order to conduct in -depth research, he has been in the United States for 8 years, completed post -doctoral research, and has also become a part -time assistant professor at Yale University School of Medicine.

From scientific research to entity, I want to take my dreams into reality

After Yinzhu learned, the original intention at the time of departure made him look back at his motherland. At this time, Central South University invested olive branches. In 2018, he returned to Hunan with his full time and established Hunan Hengya Pharmaceutical Technology Co., Ltd. with his partner to work hard in the research and development of early tumor screening technology, anti -tumor drugs and accompanying diagnostic technology.

The first measure of the Indian pillar is targeted at lung cancer, because lung cancer is the most common malignant tumor in my country. Data show that in 2020, the incidence and mortality rate of lung cancer patients in China ranks first in the world. At present, about 20%of Chinese medical examinations will find lung nodules, and some of them are lung nodules or lung cancer. Early screening of tumor is an important means to effectively reduce the incidence of cancer and increase the survival of cancer patients.

Based on the huge differences in the survival rate of Sino -US cancer patients and the huge market prospects of liquid biopsy, Professor Professor Li Kang and Professor Lai Rensheng, his two teachers, and his two teachers and Professor Lai Rensheng. robot".

From entity to affordable, I want the people to afford it

"At present, the status quo and pain point of lung cancer screening in my country lies in CT's further optional solutions and expensive prices after discovering the lung nodules. It is believed that the benign and malignant to effectively identify the lung nodules in the early stage is the key point to control the incidence of lung cancer and increase the survival rate of patients.

The goal of the early diagnosis robot is to provide a clear basis for clinicians. "Early diagnosis robots can judge in time. At present, our data has explained that the diagnosis is very high. Based on this, insurance companies are also willing to cooperate with us. Moreover, robots can accurately mutate sites and CNV from the level of the whole genome of lung cancer from the general genome level. Mutation evaluation provides a basis for subsequent individual precision treatment. "

More importantly, the team of the Indian pillars wants to reduce the cost of screening. "We don't want to make a expensive screening, so we cannot play the role of universal screening. We hope that the people can afford it, and it can really work." Yin Chizhu said that they want to make the next step early to make early early Diagnostic machines play a role in the daily prevention and treatment of ordinary people, and truly build a dam for preventing and cure diseases.

Source: China Renxian Media

- END -